Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

KIIL HARRY SKIP

Smith Gregory L

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

CNBC's Jim Cramer warns that while the current market is compared to the 1999 dot-com bubble, today's market is actually more brutal in punishing disappointing stocks. The market is heavily concentrated in AI and data center stocks while aggressively selling healthcare and medical technology companies that miss earnings expectations. Cramer defends AI investments as producing real business results, citing strong earnings from major tech companies.

Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And 1999 Is...'

The article recommends three dividend-paying stocks for long-term investors: United Parcel Service (UPS), Hormel Foods (HRL), and Medtronic (MDT). Despite being deeply unloved and trading significantly below their 2022 highs, all three companies are undergoing business transformations with early signs of success. Each offers attractive dividend yields (6.5%, 5.6%, and 3.6% respectively) and operates in essential industries, making them suitable for holding through market uncertainty.

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Medtronic, a medical device company down 40% from its 2021 peak, is attracting investor interest due to its 3.6% dividend yield and upcoming business improvements. The company is spinning off its diabetes division, launching its Hugo surgical robot to compete with Intuitive Surgical's da Vinci, and pursuing strategic acquisitions. With 48 consecutive years of dividend increases and approaching Dividend King status, analysts suggest the stock could recover as business trends improve.

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

The article recommends three high-yield healthcare stocks for retirees seeking income: Pfizer (6.5% yield) despite patent expirations, Medtronic (3.6% yield) with a 48-year dividend increase streak, and Omega Healthcare (5.8% yield), a senior housing REIT positioned to benefit from an aging population.

3 Healthcare Stocks Every Retiree Should Consider

While Intuitive Surgical dominates surgical robotics with a powerful business model, its lofty 55x P/E ratio and recent 20% drawdown make it expensive. Medtronic, trading at 22x P/E with a 3.6% dividend yield and 48 consecutive annual dividend increases, presents a more attractive buy-and-hold opportunity as it launches its Hugo surgical robot with significant growth potential.

Medtronic PLC (MDT) Stock Price, Analysis & Trade Signals